Aminogenistein 

Aminogenistein is a p56^lck inhibitor with a 1.2 μM IC₅₀. Aminogenistein inhibits production of Aβ1-40 and Aβ1-42 peptides. Aminogenistein induces accumulation of APP-CTFα and APP-CTFβ, indicating γ-secretase cleavage inhibition. Aminogenistein can be used for the research of alzheimer's disease^[1][2].

Aminogenistein (Compound 1) potently inhibits bovine thymus-derived p56^lck with an IC₅₀ of 1.2 μM, and is weakly active against protein kinase C and protein kinase A with IC₅₀ values >300 μM^[1].
Aminogenistein (24 h) dose-dependently inhibits Aβ1-40 and Aβ1-42 production in 7W CHO cells overexpressing human APP751, with IC₅₀ values of 5.7 μM and 5.8 μM, respectively^[2].
Aminogenistein (10-25 μM; 24 h) does not inhibit β-cleavage of APP in 7W CHO cells overexpressing human APP₇₅₁ at 10 μM or 25 μM^[2].
Aminogenistein (20 μM; 24 h) accumulates APP C-terminal fragments at 20 μM in 7W CHO cells overexpressing human APP751, indicating γ-secretase inhibition^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

253.26

C₁₅H₁₁NO₃

132018-32-7

O=C1C=C(OC2=CC=C(O)C=C12)C=3C=CC(N)=CC3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cushman M, et al. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src. J Med Chem. 1994 Sep 30;37(20):3353-62.

  [2]. Paris D, et al. Flavonoids lower Alzheimer's Aβ production via an NFκB dependent mechanism. Bioinformation. 2011;6(6):229-236.